Danish discovery relates to the so-called telomeres. Telomere activity is controlled by two mechanisms: erosion and addition. Addition is determined by the activity of telomerase. Telomerase consists of an RNA component (hTR) that acts to bind the telomere and a protein component (hTERT) that acts as a reverse transcriptase. Telomerase activity can be inhibited in cancerous cells and leads to a marked reduction in cellular viability and/or induces apoptosis of these cells. Anticancer approaches directed at telomerase inhibition are varied. Cancer costs us billions of dollars. It also costs us the people we love. One of the major costs of cancer is cancer treatment. Many treatment options for cancer exist, with the primary ones including surgery, chemotherapy, radiation therapy, hormonal therapy, targeted therapy and palliative care. Cancer and its treatments can affect body systems. Cancer is when abnormal iron-overloaded cells divide in an uncontrolled way. Cancer is a single disease with a single cause. Cancer is a disease of iron-overloaded cells, the Father of Oncology says. At the cellular level, cancer occurs when cellular iron overload chaotically affects cellular molecules and organelles (RNA, DNA, chromosomes, mitochondria, lysosomes, etc). Different proteins are made up of different combinations of amino acids. This gives them their own unique 3D structure and function in the body. The DNA code contains instructions needed to make the proteins. Cellular iron overload creates chaotic mistakes/errors in DNA (and in hTERT), chromosomal abnormalities, chromothripsis and mitotic catastrophes. Direct intratumoral injections of iron-deficiency agents (ceramic needles) are needed when tumors and metastases cannot be removed with surgery (ceramic blades). Clinical personalized iron-deficiency methods can neutralize micrometastases. Professor Stig Bojesen and Professor Boerge Nordestgaard can make internationally significant iron discovery in oncology.